Oncology

  • KD025 shows promise for steroid-dependent cGVHD

    on March 13th, 2018
    REPORTING FROM THE 2018 BMT TANDEM MEETINGS SALT LAKE CITY (FRONTLINE MEDICAL NEWS) – KD025, an orally available Rho-associated coiled-coil kinase 2–selective inhibitor, is demonstrating encouraging activity and safety in patients with steroid-dependent or refractory chronic graft-versus-host di[...]
  • Possible increased breast cancer risk found in women with schizophrenia

    on March 13th, 2018
    FROM JAMA PSYCHIATRY A meta-analysis has found an increased risk of breast cancer in women with schizophrenia, but its authors noted significant diversity of results across the included studies. In the meta-analysis, Chuanjun Zhuo, MD, PhD, and Patrick Todd Triplett, MD, presented the results of 12 [...]
  • A global snapshot of leukemia incidence

    on March 13th, 2018
    FROM THE LANCET HAEMATOLOGY Leukemia incidence varies considerably by geography and subtype, according to an analysis of World Health Organization cancer databases. Incidence also is generally higher in males, with a global male to female ratio of 1.4. For men, the highest regional leukemia rate –[...]
  • Gaps exist in receipt of clinically indicated genetic counseling after breast cancer diagnosis

    on March 12th, 2018
    FROM JOURNAL OF CLINICAL ONCOLOGY A minority of patients (43.5%) with an indication for breast cancer genetic risk evaluation actually received formal genetic counseling in clinical practice, according to an analysis of NCI Surveillance, Epidemiology, and End Results (SEER) data published in Journal[...]
  • Fruquintinib promising agent for advanced NSCLC

    on March 12th, 2018
    FROM JOURNAL OF CLINICAL ONCOLOGY Investigational agent fruquintinib holds promise as a third- or fourth-line treatment option for patients with advanced non–small-cell lung cancer (NSCLC), according to new findings published in the Journal of Clinical Oncology. The median progression free surviva[...]
  • Outpatient CAR T infusions feasible using liso-cel

    on March 12th, 2018
    REPORTING FROM THE 2018 BMT TANDEM MEETINGS SALT LAKE CITY (FRONTLINE MEDICAL NEWS) – A CD19-directed 4-1BB chimeric antigen receptor (CAR) T cell product showed efficacy and a low rate of cytokine release syndrome and neurotoxicity in patients with aggressive lymphomas and poor prognoses, raising[...]
  • Cancer groups offer guidance on immune-related adverse events

    on March 9th, 2018
    The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) have released new guidelines designed to help clinicians manage the unique and sometimes severe side effects associated with cancer immunotherapy agents. These guidelines meet a growing need to help[...]
  • TFR achievable with second-line nilotinib for chronic CML

    on March 9th, 2018
    FROM ANNALS OF INTERNAL MEDICINE Second-line nilotinib may lead to maintained molecular response and treatment-free remission that can last 48 weeks or longer for patients with chronic myeloid leukemia (CML), findings from a phase 2 study suggest. Treatment-free remission (TFR) is an emerging treatm[...]
  • U.S. adolescent malignant melanoma nearly halved during 2000-2014

    on March 9th, 2018
    REPORTING FROM AAD 18 SAN DIEGO (FRONTLINE MEDICAL NEWS) – U.S. incidence rates of malignant melanoma in adolescents fell by nearly half during 2000-2014, based on information from a National Cancer Institute database. The substantial drop in new cases of malignant melanoma in Americans aged 10-19[...]
  • MEC plus ixazomib looks promising in relapsed/refractory AML

    on March 8th, 2018
    REPORTING FROM ASH 2017 ATLANTA (FRONTLINE MEDICAL NEWS) – Mitoxantrone, etoposide, and cytarabine (MEC) in combination with the second-generation proteasome inhibitor ixazomib was well tolerated and effective in a phase 1 expansion study of patients with relapsed or refractory acute myeloid leuke[...]
  • Best options for treating relapsed/refractory PTCL

    on March 8th, 2018
    EXPERT ANALYSIS FROM TCLF 2018 LA JOLLA, CALIF. (FRONTLINE MEDICAL NEWS) – When patients with peripheral T-cell lymphoma (PTCL) experience relapse, consider an allogeneic stem cell transplant or clinical trial, investigators advised. Patients with relapsed PTCL have generally dismal outcomes, with[...]
  • Radiation offers no survival benefit in early lung cancer with positive margins

    on March 8th, 2018
    FROM THE JOURNAL OF SURGICAL RESEARCH For patients with early-stage non–small-cell lung cancer (NSCLC) who had positive margins following lobectomy, additional radiation therapy was not associated with a long-term survival benefit in a recent retrospective study. Positive margins were associated w[...]
  • High efficacy, no safety signals for herpes zoster vaccine post-HSCT

    on March 7th, 2018
    REPORTING FROM THE 2018 BMT TANDEM MEETINGS SALT LAKE CITY (FRONTLINE MEDICAL NEWS) – A recently approved adjuvanted herpes zoster vaccine)(Shingrix) effectively and safely prevented herpes zoster in a population of patients with multiple myeloma and other hematologic malignancies who received aut[...]
Back to top